HP and metabolic dysfunction-associated steatotic liver disease: The results of the ongoing trial in China [86] will hopefully offer insight about whether or not the association can be replicated and whether haptoglobin genotype might be a valuable predictor for the clinical response to αT treatment in NAFLD.